Key result
Concomitant administration of cyclosporine-A and ischemic postconditioning significantly reduced infarct size in diabetic rat hearts compared to controls (21% vs 39%; P<0.01).
Why the study?
Does concomitant ischemic postconditioning and cyclosporine-A reduce infarct size and improve myocardial function in diabetic rat myocardium injured by ischemia/reperfusion?
Does concomitant ischemic postconditioning and cyclosporine-A reduce infarct size and improve myocardial function in diabetic rat myocardium injured by ischemia/reperfusion?
Absolute Event Rate: 21% vs 39%
p-value: p=< .01
While ischemic postconditioning or cyclosporine-A alone fail to protect diabetic myocardium from ischemia/reperfusion injury, their combination successfully restores cardioprotection and increases nitric oxide levels.
May restore cardioprotection in diabetic models; leaves open translation to clinical ischemia/reperfusion injury.
BACKGROUND: The interaction of diabetes with cardioprotection by postconditioning in ischemia/reperfusion injury remains unclear. The aim of this study was to investigate the concomitant effects of ischemic postconditioning (IPostC) and cyclosporine-A (CsA) on nitric oxide (NO) content and parameters of cardiac function of the diabetic myocardium injured by ischemia/reperfusion. METHODS: Diabetes was induced by single injection of streptozotocin (50 mg/kg; intraperitoneally [ip]) in Wistar rats (250-320 g) and the diabetic period was 8 weeks. The hearts (n = 96) were removed quickly, mounted on Langendorff apparatus, and then subjected to 30-minute regional ischemia followed by 45-minute reperfusion. Ischemic postconditioning was induced by 3 cycles of 30-second reperfusion/ischemia at the onset of reperfusion. Myocardial function was measured throughout the experiment, and infarct size (IS) was identified by triphenyltetrazolium chloride (TTC) staining. Total amounts of NO metabolites were determined using Griess method and enzyme-linked immunosorbent assay (ELISA) reader. RESULTS: Administration of either IPostC or CsA alone in nondiabetic animals significantly improved myocardial function and reduced the ISs (28% ± 1.9% or 23% ± 2.0% vs 41% ± 2.9% of the risk zone [RZ], respectively; P < .01), but they had no effect on diabetic hearts (35% ± 1.8% or 32% ± 2.1% vs 39% ± 3.1%, respectively). In addition, myocardial NO level was significantly increased by IPostC only in nondiabetic animals (P < .01). However, after administration of CsA (5 minutes before and 10 minutes after the onset of reperfusion) in postconditioned animals, the cardioprotective and NO-enhancing effects of IPostC were restored in diabetic rats (IS: 21% ± 1.1% vs 39% ± 3.1%), similar to those in nondiabetic controls (19% ± 1.3% vs 41% ± 2.9%; P < .01). CONCLUSION: The present study indicated that IPostC or CsA failed to affect NO levels and failed to protect the diabetic myocardium against ischemia/reperfusion injury. Moreover, concomitant administration of CsA and IPostC at reperfusion can increase NO content and protect the diabetic myocardium.
No takes yet. Share an insight, caveat, or question.
Badalzadeh et al. (2011) studied Diabetic myocardium injured by ischemia/reperfusion (n=96). Concomitant ischemic postconditioning (IPostC) and cyclosporine-A (CsA) vs. Control (no treatment), IPostC alone, or CsA alone was evaluated on Infarct size as a percentage of the risk zone (p=< .01). Concomitant administration of cyclosporine-A and ischemic postconditioning significantly reduced infarct size in diabetic rat hearts compared to controls (21% vs 39%; P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: